Estrogen Receptor-Beta Expression in Hereditary Breast Cancer
Authors: Maria Grazia Daidone, Silvia Veneroni, Vera Cappelletti, Paolo Radice, Marco A. Pierotti, Mamoun Younes, Lauren Scheuer, Noah D. Kauff, Mark E. Robson, Kenneth Offit
Journal: Journal of Clinical Oncology (2002)

Article Tools SPECIAL DEPARTMENTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.99.116 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 12202682 Estrogen Receptor-Beta Expression in Hereditary Breast Cancer Maria Grazia DaidonexMaria Grazia DaidoneSearch for articles by this author , Silvia VeneronixSilvia VeneroniSearch for articles by this author , Vera CappellettixVera CappellettiSearch for articles by this author , Paolo RadicexPaolo RadiceSearch for articles by this author , Marco A. PierottixMarco A. PierottiSearch for articles by this author , Mamoun YounesxMamoun YounesSearch for articles by this author Lauren ScheuerxLauren ScheuerSearch for articles by this author , Noah D. KauffxNoah D. KauffSearch for articles by this author , Mark E. RobsonxMark E. RobsonSearch for articles by this author , Kenneth OffitxKenneth OffitSearch for articles by this author Show More Istituto Nazionale Tumori, *Fondazione Italia per la Ricerca sul Cancro, Institute of Molecular Oncology, Milan, ItalyBaylor College of Medicine, Houston, TXMemorial Sloan-Kettering Cancer Center, New York, NY https://doi.org/10.1200/JCO.2002.99.116 First Page Full Text PDF Figures and Tables © 2002 by American Society of Clinical OncologyjcoJ Clin OncolJournal of Clinical OncologyJCO0732-183X1527-7755American Society of Clinical OncologyResponse01092002In Reply:The letter to the editor by Daidone et al is intriguing and provides a possible biologic rationale for the use of hormonal therapy for breast cancer prevention in BRCA1 mutation carriers. In a recent report in the Journal of Clinical Oncology, we showed that a combination of intensive screening and “risk-reducing” surgeries led to the detection of early-stage breast and ovarian cancers in a series of 251 individuals with BRCA1 and BRCA2 mutations.1 Although these results were encouraging, they did not address the issue of chemoprevention in these patients.Other published studies examining this issue have yielded conflicting results. A case-control series by Narod et al2 showed tamoxifen lowered contralateral breast cancer risk in both BRCA1 and BRCA2 mutations carriers. However, King et al3 did not demonstrate a benefit for tamoxifen chemoprevention in BRCA1 carriers participating in the National Surgical Adjuvant Breast and Bowel Project P-1 trial. A prospective series by our group4 and a retrospective series by Rebbeck et al5 both recently reported a significant reduction in subsequent breast and BRCA-related gynecologic cancers after risk-reducing oophorectomy in BRCA1 and BRCA2 mutation carriers.However, neither of these series was powered to examine possible differences in risk-reduction between BRCA1 and BRCA2 mutation carriers. Studies such as those reported by Lakhani et al6 and Daidone et al will help to clarify the biologic mechanisms by which hormonal manipulation may alter breast cancer risk. These insights will provide the foundation for clinical trials of chemoprevention in women at highest hereditary risk for breast cancer.1. Scheuer L, Kauff N, Robson M, et al: Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutations carriers. J Clin Oncol 20:: 1260,2002-1268, Link, Google Scholar2. Narod SA, Brunet JS, Ghadirian P, et al: Tamoxifen and risk of contralateral breast cancer in and mutation carriers: A case-control study. Lancet 356:: 1876,2000-1881, BRCA1 BRCA2 Crossref, Medline, Google Scholar3. King MC, Wieand S, Hale K, et al: Tamoxifen and breast cancer incidence among women with inherited mutations in and . JAMA 286:: 2251,2001-2256, BRCA1 BRCA2 Crossref, Medline, Google Scholar4. Kauff ND, Satagopan JM, Robson ME, et al: Risk-reducing salpingo-oophorectomy in women with a or mutation. N Engl J Med 346:: 1610,2002-1615, BRCA1 BRCA2 Google Scholar5. Rebbeck TR, Lynch HT, Neuhausen SL, et al: Prophylactic oophorectomy in carriers of or mutations. N Engl J Med 346:: 1616,-1622BRCA1 BRCA2 Crossref, Medline, Google Scholar6. Lakhani SR, van de Vijver MJ, Jacquemer J, et al: The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in and . J Clin Oncol 20:: 2310,2002-2318, BRCA1 BRCA2 Link, Google Scholar